Metastases and Colon Cancer Tumor Growth Display Divergent Responses to Modulation of Canonical WNT Signaling

• Published in: PloS one Vol. 11; no. 3; p. e0150697
• Main Authors: Seth, Chandan, Ruiz i Altaba, Ariel
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 03.03.2016; Public Library of Science (PLoS)
• Subjects: Adenomatous polyposis coli; Animals; Antagonists; B cells; Biocompatibility; Biology and Life Sciences; Biomedical materials; Cancer; Cancer metastasis; Cell culture; Cell Line, Tumor; Cell Proliferation; Colon; Colon cancer; Colonic Neoplasms - metabolism; Colonic Neoplasms - pathology; Colorectal cancer; Engineering and Technology; Female; Gastrointestinal diseases; Genetic aspects; Growth; Hepatocyte Nuclear Factor 1-alpha - metabolism; Humans; In vivo methods and tests; Infections; Intestine; Lac Operon; Lentivirus - metabolism; Ligands; Medicine and Health Sciences; Metastases; Metastasis; Mice; Mice, Nude; Mutation; Neoplasm Metastasis; Neoplasm Transplantation; Phenotype; Polymerase Chain Reaction; Research and Analysis Methods; RNA-mediated interference; Signal transduction; Signaling; Species Specificity; Stem cells; Tumors; Wnt protein; Wnt Proteins - metabolism; Wnt Signaling Pathway; Xenografts; Switzerland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0150697

Human colon cancers commonly harbor loss of function mutations in APC, a repressor of the canonical WNT pathway, thus leading to hyperactive WNT-TCF signaling. Re-establishment of Apc function in mice, engineered to conditionally repress Apc through RNAi, resolve the intestinal tumors formed due to hyperactivated Wnt-Tcf signaling. These and other results have prompted the search for specific WNT pathway antagonists as therapeutics for clinically problematic human colon cancers and associated metastases, which remain largely incurable. This widely accepted view seems at odds with a number of findings using patient-derived material: Canonical TCF targets are repressed, instead of being hyperactivated, in advanced colon cancers, and repression of TCF function does not generally result in tumor regression in xenografts. The results of a number of genetic mouse studies have also suggested that canonical WNT-TCF signaling drives metastases, but direct in vivo tests are lacking, and, surprisingly, TCF repression can enhance directly seeded metastatic growth. Here we have addressed the abilities of enhanced and blocked WNT-TCF signaling to alter tumor growth and distant metastases using xenografts of advanced human colon cancers in mice. We find that endogenous WNT-TCF signaling is mostly anti-metastatic since downregulation of TCF function with dnTCF generally enhances metastatic spread. Consistently, elevating the level of WNT signaling, by increasing the levels of WNT ligands, is not generally pro-metastatic. Our present and previous data reveal a heterogeneous response to modulating WNT-TCF signaling in human cancer cells. Nevertheless, the findings that a fraction of colon cancers tested require WNT-TCF signaling for tumor growth but all respond to repressed signaling by increasing metastases beg for a reevaluation of the goal of blocking WNT-TCF signaling to universally treat colon cancers. Our data suggest that WNT-TCF blockade may be effective in inhibiting tumor growth in only a subset of cases but will generally boost metastases.